{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:30:25Z","timestamp":1762475425325,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jdcr.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T07:08:30Z","timestamp":1665644910000},"page":"83-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Durvalumab-associated generalized morphea with overlapping vitiligo"],"prefix":"10.1016","volume":"30","author":[{"given":"Julianna","family":"Martel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Cheal","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-8575","authenticated-orcid":false,"given":"John S.","family":"Runge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Tayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celyne Bueno","family":"Hume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Curry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Heberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2022.10.007_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jdcr.2022.10.007_bib2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.10.007_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jdcr.2022.10.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jdcr.2022.10.007_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.jdcr.2022.10.007_bib6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.jdcr.2022.10.007_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11882-013-0418-0","article-title":"Genotyping for severe drug hypersensitivity","volume":"14","author":"Karlin","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jdcr.2022.10.007_bib8","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jdcr.2022.10.007_bib9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262200460X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262200460X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:13Z","timestamp":1762475113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251262200460X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":9,"alternative-id":["S235251262200460X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.007","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab-associated generalized morphea with overlapping vitiligo","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access..","name":"copyright","label":"Copyright"}]}}